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Abstract: Escherichia coli (E. coli) has been established to be a native producer of succinic acid (a 
platform chemical with different applications) via mixed acid fermentation reactions. Genome-scale 
metabolic models (GEMs) of E. coli have been published with capabilities of predicting strain design 
strategies for the production of bio-based succinic acid. Proof-of-principle strains are fundamentally 
constructed as a starting point for systems strategies for industrial strains development. Here, we 
review for the first time, the use of E. coli GEMs for construction of proof-of-principles strains for 
increasing succinic acid production. Specific case studies, where E. coli proof-of-principle strains 
were constructed for increasing bio-based succinic acid production from glucose and glycerol carbon 
sources have been highlighted. In addition, a propose systems strategies for industrial strain 
development that could be applicable for future microbial succinic acid production guided by GEMs 
have been presented. 
Keywords: bio-succinic acid production; Escherichia coli strain design; genome-scale metabolic 
models; proof-of-principle strains 
 
1. Introduction  
Succinic acid is a platform chemical with a variety of applications in various field and it served 
as starting chemical for the production of other commodity and specialty chemicals Figure 1 [1].   
E. coli has been established to be a native producer of succinic acid under anaerobic conditions in a 
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mixed acid fermentation reactions using glucose carbon source [2,3]. Metabolic engineering 
strategies involving various gene manipulations to overproduce succinic acid in E. coli using 
experimental trial and error approach [4,5] have been reported elsewhere [2,4,6,7,8]. 
E. coli genome-scale metabolic models (GEMs) have been developed and published [9,10] with 
ability to predict metabolic engineering capabilities for increasing production of desired compound 
of interest consistent with that of experimental approaches [11,12,13]. E. coli GEMs have been 
applied for predicting metabolic engineering interventions for increasing succinate production faster 
than the conventional approach of experimental trial and error [14,15,16]. We recently constructed 
proof-of-principles strains of E. coli using GEMs for increasing succinic acid production from 
glucose, and glycerol carbon sources [14,15,16]. 
Systems metabolic engineering integrating genome-scale metabolic modelling and omics 
analysis could help in developing superior microbial strains that can produce industrially relevant 
titer of a desired compound. Although constraint based modelling can serve as starting point to 
identify novel gene targets (knockouts, over and/or under expression) to create proof-of-principle 
strains and it can be used iteratively at various stages of the ten strategies previously reported by lee 
and colleagues [17]. The implementation of the strategies (see Table 3) proposed by lee and 
colleagues [17], enabled bio-based succinic acid production from Mannheimia succiniciproducens [18] 
and Basfia succiniciproducens [19]. 
Here we discuss E. coli genome-scale metabolic model’s perspective in guiding much faster 
metabolic engineering strategies for constructions of proof-of-principle strains that could serve as a 
starting point for systems strategies in industrial strain development. Specific case studies of 
proof-of-principle E. coli strains constructed have been summarized in Table 2 and further proposed 
that ten strategies (see Table 3) applied elsewhere to produce L-arginine [20], L-lysine [21], and 
nylon from Corynebacterium glutamicum respectively [22]. This approach could also be applicable 
for bio-based succinic acid production using E. coli predictive potentials (since its GEMs have been 
published) and/or other succinic acid producing microorganism that could be discovered in the 
future. 
2. Succinic Acid 
Succinic acid is a bulk chemical with an estimated world production rates ranging between 
30,000 to 50,000 tons annually [23]. The compound annual growth rate of its market is expected to 
reach 18.7% from 2011 to 2016 [23]. The conventional production of succinic is achieved via 
petrochemical process from butane or benzene through the conversion of maleic anhydride to 
succinic anhydride followed by subsequent hydrolysis. Other alternative routes for succinic acid 
production include the carbonylation of ethylene glycol and the oxidation of 1, 4-butanediol [24]. 
These petrochemical-based productions are expensive and pose serious environmental concerns. 
2.1. Application and market for succinic acid 
Succinic acid has a wide range of industrial applications. Succinic acid and its derivatives have 
applications as food ingredients, starting material for the manufacture of active pharmaceutical 
ingredients and/or pharmaceutical additives. It also has applications as surfactants/detergent extender, 
ion chelator, as flavoring agent [1] and as well as de-icing agent in aviation sector [25]. Succinic acid 
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has been reported to be in the list of the US department of Energy’s 12 top bio-based chemicals that 
are produced using fermentation of microorganisms from renewable feedstock [5,23]. In addition, it 
was identified to be a building block chemical with a variety of applications [23]. Four major 
existing markets for succinic acid has been previously identified [1]. These markets include: (i) 
surfactant/detergent extender, which is considered as the largest, (ii) used in electroplating for 
prevention of corrosion and painting of metals (ion chelator), (iii) used as food additives, flavouring 
agents, and (iv) used in the production of pharmaceuticals, antibiotics, amino acids and     
vitamins (health-related applications). 
Succinic acid derived from fermentation could have the potentials to become a precursor for the 
synthesis of commodity chemical that could serve as routes for providing a number of essential 
intermediates with applications in other industries. Succinic acid, has the potential to replace a 
number of commodities based on petrochemical intermediates and benzene, which could prevent 
pollution from manufacturers and the consumption of benzene-derived chemicals [1]. The potential 
routes map leading to succinic acid-based intermediates and specialty chemical is illustrated in 
Figure 1. These routes indicates where succinic acid can be a building block chemical for syntheses 
of commodity and specialty chemicals. Succinic acid is a linear saturated dicarboxylic acid, as such it 
can be used as a starting chemical to synthesize 1,4-butanediol, tetrahydrofuran, γ-butyrolactone and 
other chemicals, that could have a range of global application in various fields. 
 
Figure 1. Succinic acid as a platform chemical for syntheses of other specialty and 
commodity chemicals. Partially adopted from Zeikus and colleagues [1]. 
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3. Escherichia coli Genome-Scale Metabolic Models 
Interaction of cell components with one another within the cell serve as bases for cellular 
functions from biochemical reactions. Cheap DNA sequencing and increase genome data availability, 
lead to a large number of biochemical data from cell component interactions, that can be organized 
and assembled in a form of reconstruction known as genome-scale models [26]. The computational 
model nowadays called reconstruction or GEM is generated from the wealth of biochemical 
information or data obtained by experimentation. The model has the capability to predict biological 
phenomena that are linked to genotypic and phenotypic functions, which usually uses a user define 
environmental and genetic parameters [26]. Both the parameters are well accounted for in an ideal 
GEM, paving a conspicuous way for increasingly accurate genotype-phenotype relationship 
prediction in a designated environmental conditions [26]. Genome-scale metabolic model has 
recently become foundational to understanding cells metabolic capabilities at systems-level and its 
noticeable uses in systems metabolic engineering [27]. A genome scale model (GEM) is usually 
constructed based on extensive collections and curation of the known biological information that 
contained gene annotation and functions, metabolites, metabolic reactions, enzymes and their overall 
reactions within an organism [27]. 
The E. coli GEM represent the best-validated GEM so far. This is largely due to the wealth of its 
experimental data availability and the simplicity of its network structure [27]. The first E. coli model 
was reported in 2000 and later updated as more is known on its biochemical reaction       
network (reactome) [26]. There are two most popular E. coli GEMs available in the literature and 
both can be downloaded from either the Biomodels database [28] or BiGG [29]. The Feist model 
designated as iAF1260, was published in 2007 which contained up to 1260 open reading frame [9]. 
This model contains 1,668 metabolites, 2,382 metabolic reactions (see Table 1) [9]. Using the new 
biochemical information (data) and conditional essentiality analysis, the model was further updated 
to the most recent version called the Orth model, designated as iJO1366 (see Table 1). This model 
was reported to accounts for 1,366 genes, 1,805 unique metabolites and 2,583 metabolic    
reactions [10] (see Table 1). In addition, an expanded GEM of E. coli has been published in 2013 
called genome-scale metabolism and gene expression, designated as iOL1650-ME model [30]. This 
model was equally reported to have 1,683 genes, 12,009 reactions, and 6,563 unique metabolites [30]. 
These most recent models mentioned above were reconstructed by taking into account, elements and 
charged balance reactions, thermodynamic consistency and gene-reaction protein associations [9,10] 
These features are considered critical in improving the ability of models’ accurate predictions of 
cellular phenotype and gene essentiality [9]. 
Table 1. E. coli genome-scale metabolic models with different size and scope. 
Models Reactions Genes Metabolites/Components References 
iAF1260 2,382 1,260 1,668 [9] 
iJO1366 2,583 1,366 1,805 [10] 
iOL1650-ME 12,009 1,683 6,563 [30] 
3.1. Escherichia coli proof-of-principle strains constructed using GEMs for succinate production 
Strain design strategies for bio-based industrial production of succinic acid requires 
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system-wide approaches combining systems and synthetic biology tools to create superiors strains 
taking into consideration the fermentative strain performance at industrial scale. GEMs have been 
developed and widely used for strain design and biological discovery [9,10,11,31,32]. GEMs of    
E. coli have varying scope and their capabilities to predict metabolic engineering strategies 
considerably varies from one GEM to the next (see Table 1).  
E. coli GEMs have been used for construction of proof-of-principle strains that enhances succinic 
acid production from two most important carbon sources, glucose, an glycerol [14,15,16,33,34,35]. The 
proof-of-principle strains constructed from our previous studies leverages the predictive metabolic 
engineering strategies using E. coli GEMs (in silico-driven hypotheses building), which reduces, 
time, cost, and labor intensive processes involved in identification of novel gene deletion targets, 
when compared with the conventional experimental trial and error approach (which is time 
consuming, expensive and labor intensive). A reasonable increase production of succinic acid have 
been achieved, though not industrially relevant titer but rather at proof-of-principle stage. This stage 
is considered as one of the fundamental stages in strain design and development strategies for 
industrially relevant performance. The strain constructed using GEM include BMS1 (ΔatpE),  
BMS2 (Δgnd), BMS4 (ΔfdoH), with both predicted and experimentally confirmed increase in 
succinate production from glucose and glycerol carbon sources (see Table 2). Additionally, in silico  
Table 2. E. coli proof-of-principle strain constructed for increasing succinic acid 
production from glucose and glycerol carbon sources. 
Strains Target genes Carbon 
source used 
Predicted 
using GEMs? 
Experimentally 
confirmed? 
Fermentation 
time (days) 
Succinate 
production (g/l) 
References 
Wild-type - glucose Yes Yes 2 0.16 [36] 
BMS1 ΔatpE glucose Yes Yes 2 0.44 [36] 
BMS2 Δgnd glucose Yes Yes 2 0.29 [14] 
BMS4 ΔfdoH glucose Yes Yes 2 0.45 [16] 
Wild-type - glycerol Yes Yes 7 0.02 [36] 
BMS1 ΔatpE glycerol Yes Yes 7 1.39 [36] 
BMS2 Δgnd glycerol Yes Yes 7 0.67 [14] 
BMS4 ΔfdoH glycerol Yes Yes 7 2.06 [16] 
ptsG/b1101 ΔptsG glycerol Yes Not yet - - [35] 
pntA/b1603 ΔpntA glucose Yes Not yet - - [33] 
glpC/b2243 ΔglpC glycerol Yes Not yet - - [34] 
Wild-type - glucose Yes Yes 1 0.29 [37] 
W311OGFA ΔptsG, 
ΔpykFA 
glucose Yes Yes 1 0.96 [37] 
W311OGFA ΔptsG, 
ΔpykFA 
glucose Yes Yes 3 2.05 [37] 
W311OGFAP ΔptsG, 
ΔpykFA, 
Δpfl 
glucose Yes Yes 3 0.99 [37] 
W311OGFAP ΔptsG, 
ΔpykFA, 
Δpfl, ΔldhA 
glucose Yes Yes 3 0.05 [37] 
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strains were constructed namely: ptsG/b1101, pntA/b1603, and glpC/b2243 that shows predicted 
increase in succinate production with not yet experimentally verified outcomes [33,34,35]. 
Other researchers have reported the use of E. coli GEMs for gene knockout simulation 
predicting increase in succinic acid production from glucose [37]. Their predicted and experimentally 
confirmed findings indicated increase succinic acid production in E. coli from glucose (see Table 2). 
The strains constructed contained combinatorial gene knockouts to increase succinic acid production 
from glucose. These strains include: W311OGFA (ΔptsG, ΔpykFA), W311OGFA (ΔptsG, ΔpykFA), 
W311OGFAP (ΔptsG, ΔpykFA, Δpfl) W311OGFAP (ΔptsG, ΔpykFA, Δpfl, ΔldhA) [37]. These strains 
were found to have increase in succinic acid production higher than their wild-type counterparts (see 
Table 2). None of the proof-of-principle strains constructed have reached industrially relevant titer, as 
it is considered as an initial stage of strain design strategies that could be further improved by 
applying recent ten strategies described by lee and colleagues [17]. For step by step brief description 
of the strategies that can be applicable to obtain industrially relevant performing strain with high 
yield titer and productivity, please kindly see Table 3. 
Table 3. Ten systems strategies for constructing superior industrial strains. 
Strategies Brief descriptions Expected inferences 
1. Project design Project design should be conducted for the target product 
and other plausible scenarios should be explored such as, 
cost-effective carbon source, aerobic and/or anaerobic 
fermentation, and downstream strategies and equipment 
to be used. Other key performance indices to be 
considered are: product titer, yield, and productivity in 
the context of bioprocess development and whether it 
could be economically competitive. In addition, systems 
and synthetic biology tools are becoming more available 
to make microorganisms of interest tractable to genetic 
manipulations within shortest possible time. With the 
recent development in synthetic biology gene-editing 
technology called CRISPR (clustered, regulatory 
interspaced, short palindrome repeats)-Cas9 
(CRISPR-associated protein)-based systems offered 
considerable advantage for engineering microorganisms 
that were previously reported to be not amenable to genetic 
manipulations [17]. 
Technical, economical and regulatory 
factors are considered during project 
design and they should be strictly adhered 
to, as microbial engineering are involved 
and are considered as genetically modified 
organism (GMO) [17]. The microbial 
chassis strain constructed and their target 
products are classified as GMOs and they 
fall under different GMOs international 
regulations and different jurisdictions [17]. 
The regulations should be adhered to for 
safety.  
2. Selection of chassis 
host 
Chassis host should be carefully selected based on the 
availability of tools for its easy improvement or genetic 
manipulation for the increase production of target 
compound. E. coli and S. cerevisiae have been used more 
often than not, but some researchers are of the opinion 
that new host should be explored for biobased production 
of certain compounds, but this depends on the availability 
of resources and researchers’ wisdom to explored the new 
host for the targeted project objectives. 
Microbial chassis host selection is 
expected to take into consideration the 
target products, substrate utilization, strain 
tolerance to certain metabolic and 
physiological profiles such as pH in case 
of acids (e.g. lactic acid and succinic 
acid). The consideration for downstream 
processing, and purification cost should be 
carefully considered.  
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Additional factors are considered in careful strain 
selection, such as carbon substrate utilization range, ease 
of fermentation on a cheap medium, ease of scale up, and 
requirements for aerobic and/or anaerobic conditions 
[17]. For example, succinic acid and lactic acid 
production requires a strain that is tolerant to low pH, 
because the purification of dissociated acid end product 
could be expensive when fermentation are performed under 
neutral pH [17]. 
3. Metabolic pathway 
reconstruction 
The candidate metabolic pathways leading to the 
production of the target compound may or may not be 
present in the select chassis host. If it is present, then the 
host is a native producer of the target compound e.g. 
succinic acid in E. coli. If the pathway is absent in the 
chassis host e.g. 1, 4-butanediol production in E. coli , the 
researchers need to establish the pathway by carefully 
identifying the candidate enzymes and/or genes via 
mining genomes and metagenomes. 
Natural producer cells are expected to 
undergo re-engineering to block byproduct 
formation, decrease and/or increase 
precursor formation for the target 
compound and/or otherwise. Sometimes 
researcher need to introduce foreign genes 
that could help in increasing compound 
titers in native producer chassis host. On 
the other hand, heterologous pathways can 
be designed from other organisms for 
non-native producers of the target 
compound of interest. In this case, it is 
expected that optimization strategies 
should be employed to increase the 
performance of the foreign pathway 
introduced into the chassis host for 
optimal performance. 
4. Tolerance of 
product Toxicity 
Some products at certain requisite level of say 50–80% 
tends to inhibit cell’s growth. Increasing tolerance level 
of the target strain design is of utmost importance. This 
can be achieved by developing product-tolerance strains 
by serial subculturing of cells with increasing 
concentration of product with or without mutagen 
treatment, followed by identification of cells that grow 
faster [17]. This could gradually increase the strain design 
tolerance to its target product. 
It is expected that the strategies could 
increase product tolerance in the chassis 
host. This will be interesting so that it will 
not be toxic to the production host, giving 
it ability to produce industrially relevant 
titer and productivity. A chassis host that 
has been designed using this strategy is 
expected to be tolerant to the target 
compound which will offer considerable 
advantage in terms of industrially relevant 
performance.  
5. Removal of negative 
regulatory circuits 
Biological networks have negative feedback loops that 
influences genes expression and signal transduction 
profiles. Negative regulatory circuits that affects 
metabolic engineering cause transcriptional attenuation 
control and feedback inhibition during amino acids 
biosynthesis [17]. Transcriptional attenuation control 
could be addressed by replacing promoters of the target 
The production of certain compounds 
from microbial chassis could be affected 
by negative regulatory circuits. There are, 
as yet, other regulatory circuits that could 
be uncovered in the future. If they serve as 
bottlenecks for overproducing a target 
compound in a chassis host, their removal 
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metabolic enzymes with constitutive ones and/or 
removing genes encoding regulators that represses amino 
acids biosynthesis [17]. 
and/or attenuation become necessary to 
increase titer and productivity. Therefore, 
a chassis host devoid of negative 
regulatory circuit could ultimately 
increase the production of the target 
compound that can reached industrial 
relevant titer. 
6. Changing flux 
directions to optimize 
cofactor and/or precursor 
availability 
Increasing availability of cofactors increases the 
production of target compounds. Cofactor such as NADH 
is involved in many biochemical reactions and sometimes 
serves as precursor for the production of certain 
compound, eg Succinic acid production in E. coli require 
2 mole of NADH to make 1 mole of Succinic acid from 
glucose. Therefore, deleting competing reactions 
(metabolic gene knockouts) that consumes NADH will 
ultimately increase precursor availability to be utilized in 
target compound production such as succinic acid in E. 
coli.  
Changed flux directions by metabolic gene 
knockout of competing pathways 
(preserving additional cofactor and/or 
precursors such as NADH, NADPH) and 
minimizing by-products formation. 
Chassis host that is engineered to 
optimized cofactor and/or precursor 
availability would ultimately increase 
target compound production that might 
reach industrially relevant titer and 
productivity. Succinic acid production can 
be increased by increasing the availability 
of NADH in microbial chassis host.  
7. Optimizing 
metabolic fluxes toward 
product formation and its 
diagnosis 
Fluxes should be optimized using fed-batch fermentation 
at laboratory conditions, as the fed-batch fermentation are 
often required for standard industrial fermentative 
production of the target compound. This should be clearly 
taken into consideration during strain design and 
development. This involve iterative design and diagnosis 
at the laboratory scale before moving to industrial scale 
production. 
Fluxes to fermentative end product can be optimized by 
removing identified bottlenecks, diverting flux from 
branch pathways or even blocking secretion of 
byproducts, which can reduce the operation costs for 
product separation and purification in downstream 
processes 5 [17,38,39]. 
Production performance of the target 
strain need to evaluated and diagnosed 
using key indicators such as productivity, 
yield and titer. The metabolic 
intermediates should be carefully 
evaluated and diagnosed by optimizing 
metabolic fluxes towards the end product 
of interest. This strategy is expected to 
have effect on the substrate consumption 
by the chassis and its ability to produce 
the required end product to reach 
industrially relevant titer. Depending on its 
outcome, the subsequent objective that 
could address the next round of metabolic 
engineering can be proposed. 
8. Optimization of 
microbial culture 
conditions and its 
diagnosis 
In order to obtain an optimized microbial culture 
conditions for high performance, productivity, yield and 
titer of the target compound, one need to examine the 
availability of substrates and/or feed stocks with its 
surrounding economics. The ability of the host chassis to 
efficiently utilize the chosen carbon source is also an 
important consideration. Although chemically defined 
media is preferred compared to complex media, because 
of its desirability in both laboratory and industrial scale 
Selection of suitable feedstock or carbon 
source that is cheaper, and ultimately 
abundant for microbial utilization is of 
utmost importance. The strain should have 
efficient substrate utilization rates in 
relation to the target compound 
production. The strain should be 
re-examined on different carbon sources, 
such as glycerol, glucose, xylose, and 
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fermentation, and thus allow precise metabolic analyses 
of the chassis host and high efficiency in experimental 
reproducibility when compared to the complex media that 
could be expensive. e.g. optimized culture conditions 
using glucose and/or glycerol substrate could be used to 
produce succinic acid from microbial chassis host. 
sucrose depending on their availability, 
economic profiles, and the target 
compound being produced. Careful 
diagnosis of these carbon sources and 
other conditions are expected to produce 
high performance microbial chassis for the 
production of the compound of interest. 
9. System-wide gene 
manipulation for 
increasing production 
This strategy seek to identify system-wide evaluation of 
gene manipulation targets that could ultimately increase 
production capability of the target strain. This strategy is 
often considered as the final round of engineering 
approach for final industrial strain. The strategy can be 
achieved by applying systems and synthetic biology 
methods such as cultivation-based profiling and systems 
wide analyses, high-throughput genome-scale 
engineering, in silico metabolic simulations and/or 
omics-based approaches. 
Though require development of new tools 
and strategies for engineering microbial 
host cells other than E. coli and S. 
cerevisiae, it is considered as a stage that 
can evaluate, diagnose, and reexamined 
the final laboratory fed batch fermentation 
of the target strain in relation to the 
different approaches employed before 
industrial scale-up fermentation. Certain 
outcomes obtained at this stage may 
suggest iterative revisiting of an earlier 
decision and vice versa. 
10. Scale-up 
fermentation of the 
designed strain and its 
diagnosis 
Strain designed at bench scale and/or laboratory scale 
with desired characteristics could have a different 
performance under real pilot plant or demo plant 
fermentation for scale up [17]. Such discrepancies of 
strain displaying different characteristics at laboratory 
and pilot scales are often very difficult to be predicted at 
the inception. Therefore, this stage requires actual demo 
or pilot scale fermentation to be conducted for the desired 
chassis of interest. The outcomes of such fermentation 
profile of the constructed strain should be evaluated and 
diagnosed for possible discrepancies that might be 
attributed to genetic instability of the chassis host and/or 
substrate consumption or utilization at different 
fermentation stages [17]. 
The strain at this stage is expected to have 
stability and industrially relevant 
performance (e.g. titer, yield, and 
productivity) at the laboratory stage and 
pilot or demo plant fermentation stages.  
Failure in scale-up fermentation stage may 
occur when certain stages in the systems 
strategies were not adequately and 
carefully conducted and diagnosed [17]. 
e.g. failure to do actual pilot or demo plant 
characterization after the flask or 
fed-batch culture fermentation conducted 
at the laboratory scale. 
4. Systems Strategies That Could Be Used to Increase Industrial Bio-Succinic Acid 
Production in the Future 
To achieve microbial bio-based succinic acid production at industrial scale, an integrated 
approach combining systems-wide metabolic engineering and optimization of cellular metabolism is 
of utmost importance. This approach is expected to combine strain development (upstream), 
fermentation (midstream), and separation and purification (downstream). This approach entails ten 
different strategies that should be carefully adhered to in an iterative fashion to achieve biosynthetic 
goal of developing microbial chassis strains that can produce industrially relevant titer, yield, and 
productivity of succinic acid using cost effective manner. The ten  strategies demonstrated 
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elsewhere [17] and summarized in Table 3 could be used in the future for bio-based succinic acid 
production using cheaper carbon substrate with microbial chassis host. The ten systems strategies for 
developing industrially relevant strain are briefly summarized with their corresponding expected 
outcomes in Table 3. For detailed strategies and inner working of the strategies, we refer the reader to 
the most recently published perspective reported elsewhere [17]. A noteworthy contribution of the 
ten strategies summarized in Table 3 is evident, as it has been used for bio-based production of 
L-arginine [20], L-lysine [21], and nylon [22] all from metabolically engineered Corynebacterium 
glutamicum. In a different study, the ten strategies for industrial strain development was used to 
directly overproduce 1,4-butanediol in metabolically engineered E. coli strain [40].  
5. Conclusions and Perspectives 
In this mini review, we describe brief applications of succinic acid as a platform chemical and 
the need to produce it via bio-based route, as a green technology. We further discuss the 
constructions of proof-of-principle strains, with specific published case studies from E. coli GEMs 
for increasing succinic acid production from glucose, and glycerol carbon sources. We additionally 
proposed that systems-wide strategies combining, metabolic engineering, systems biology and 
synthetic biology tools could be deployed to address the current challenge of achieving industrially 
relevant titers for bio-based succinic acid production from microbial chassis host. 
The need for identification of new microorganisms capable of producing succinic acid is of 
utmost importance in this post genomic era. Genome-scale metabolic models of these organisms 
need to be developed and make them tractable and/or amenable for genetic manipulation to allow the 
deployment of toady’s systems and synthetic biology tools including CRISPR-Cas9 gene editing 
technology to create robust microbial chassis for the production of succinic acid and/or any target 
compound of interest. 
A noteworthy contribution of quality GEMs in systems strategies for strain development is 
highly recognized [32,37], although currently we have different GEMs of E. coli with varying scopes 
and gaps. For example, there are two types of E. coli GEMs namely, metabolism model (M-Model) [9,10] 
and metabolism and gene expression model (ME-model) [30]. The former (M-model), predict only 
reaction fluxes in the metabolic network while the later (ME-model), has the capability of predicting 
the cell’s entire proteome [12]. Therefore, careful development and selection of GEMs in predicting 
metabolic engineering strategies could reduce the time, cost and labor intensive processes involved 
in systems strategies for strain development. The use of accurate GEMs is of great importance, and 
the deployment of recent advanced systems metabolic engineering tools in systems strategies for 
creation of superior industrial strains is also of utmost importance.  
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